- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613313
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lipomas are common mesenchymal, benign, fatty tumors of varying sizes that occur in the general adult population. They usually present as painful or annoying lumps that are palpable and often visible in the subcutaneous tissue. Many subcutaneous lipomas are asymptomatic and are removed for non-medical reasons. However, they may cause the subject pain or discomfort or interfere with normal activity.
Spontaneous remission of lipomas has not been reported. A lipoma, once it presents itself, remains there for the lifetime of a person who carries it and may stay small or become larger. Alternative treatments of the lipoma are surgery or liposuction. If a large excision is performed there is the problem of having a very large scar and the accompanying issues of healing a large scar, or possible formation of a hematoma followed by consolidation of the hematoma and the remnants of a mass of scar tissue. This is often painful and more problematic than the original lipoma. liposuction also has the potential for hematoma formation followed by scar mass residual.
To avoid the complications listed above, a non-invasive method of treatment, such as enzyme mediated disassociation of adipose tissue, would be desirable. The primary aim of this study is to perform a step-wise approach in dosing to evaluate the safety and efficacy of clostridium histolyticum as a non-operative treatment for lipoma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Hewlett, New York, United States, 11557
- Zachary E. Gerut, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical history lipoma at least one year and no treatment within last 90 days
- Lipoma diagnosed as benign
- Lipoma is a single mass with easily definable edges
- Lipoma has an area of 2.0 to 17 cm squared
- Women of childbearing potential must use an acceptable method of birth control
Exclusion Criteria:
- Lipomas on the head, neck, hand or foot, or female breast
- Women who are nursing or pregnant
- Subjects who have participated in any investigational drug trial within 45 days of enrollment in this study
- Subjects with known allergy to collagenase or any of the inactive ingredients in XIAFLEX
- Subjects with diabetes or any medical condition that would make the subject unsuitable for enrollment.
- Subjects having a history of trauma in the area of the lipoma
- Subjects with a history of connective tissue diseases or rheumatological diseases.
- Subjects with uncontrolled hypertension
- Subjects currently receiving or planning to receive anticoagulant medication except for less than 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days before injection of study drug
- Subjects having the following laboratory abnormalities:
- ALT/AST greater than 3 times the upper limit of normal
- Creatinine greater than 2
- Hemoglobin/hematocrit and WBC outside the normal range
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose #1
single injection 0.058 mg Collagenase Clostridium Histolyticum
|
This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Other Names:
|
Experimental: Dose #2
single injection 0.15 mg Collagenase Clostridium Histolyticum
|
This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Other Names:
|
Experimental: Dose #3
single injection 0.29 mg Collagenase Clostridium Histolyticum
|
This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Other Names:
|
Experimental: Dose #4
single injection 0.44 mg Collagenase Clostridium Histolyticum
|
This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visible Surface Area of the Lipoma
Time Frame: Baseline and Six months post injection of study drug
|
The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width).
Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.
|
Baseline and Six months post injection of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Change in Volume of the Lipoma
Time Frame: Baseline and 6 months post injection of study drug
|
A secondary outcome is the relative change in volume of the lipoma as determined by MRI.
This outcome will be analyzed as the change from baseline to 6 months post injection.
|
Baseline and 6 months post injection of study drug
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Zachary E Gerut, M.D., Gerut, Zachary, M.D.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Lipoma DE/01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipoma
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustUnknownLipoma of Spinal CordUnited Kingdom
-
Universidade Metropolitana de SantosRecruiting
-
Kythera BiopharmaceuticalsCompleted
-
Suez Canal UniversityCompleted
-
Gerut, Zachary, M.D.Advance Biofactures CorporationCompleted
-
Kythera BiopharmaceuticalsCompleted
-
Ruhr University of BochumCompletedSoft Tissue Sarcoma | Tumor | LipomaGermany
-
Pennington Biomedical Research CenterLipotheraCompleted
-
Yonsei UniversityCompletedVesico-Ureteral Reflux | Filum Terminale LipomaKorea, Republic of
-
University of MichiganAmryt PharmaActive, not recruitingLipomatosis, Multiple SymmetricalUnited States
Clinical Trials on Collagenase Clostridium Histolyticum
-
Stony Brook UniversityCompletedAdhesion of Flexor Tendon of HandUnited States
-
Endo PharmaceuticalsCompletedEdematous SkinUnited States
-
Endo PharmaceuticalsCompleted
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Advance Biofactures CorporationCompletedLeiomyoma | Fibroids, UterineUnited States
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedCellulite | Edematous Fibrosclerotic PanniculopathyUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic PanniculopathyUnited States
-
University of MiamiEndo PharmaceuticalsRecruitingSexual Dysfunctions, Psychological | Genital Diseases, Male | Peyronie DiseaseUnited States